688621 阳光诺和
已收盘 11-22 15:00:01
资讯
新帖
简况
阳光诺和：公司现在的新签订单中临床业务的占比已经接近50%
每日经济新闻 · 11-20
阳光诺和：公司现在的新签订单中临床业务的占比已经接近50%
阳光诺和：本公司暂未涉足CDMO委托生产服务领域
每日经济新闻 · 11-20
阳光诺和：本公司暂未涉足CDMO委托生产服务领域
阳光诺和：11月15日接受机构调研，中金证券、国投瑞银等多家机构参与
证券之星 · 11-19
阳光诺和：11月15日接受机构调研，中金证券、国投瑞银等多家机构参与
阳光诺和：本公司自主研发并储备的产品，多于临床批件获取前后实现转让，并同时锁定后续服务
证星董秘互动 · 11-19
阳光诺和：本公司自主研发并储备的产品，多于临床批件获取前后实现转让，并同时锁定后续服务
阳光诺和2024Q3财报点评：Q3营收高增 自研品种不断推进
长江证券 · 11-17
阳光诺和2024Q3财报点评：Q3营收高增 自研品种不断推进
11月15日阳光诺和跌5.14%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 11-15
11月15日阳光诺和跌5.14%，融通健康产业灵活配置混合A/B基金重仓该股
阳光诺和大幅下跌 获融资净买入1127万元
智选洞察 · 11-15
阳光诺和大幅下跌 获融资净买入1127万元
阳光诺和：关于董事暨审计与风险委员会委员辞职的公告
新浪财经-鹰眼工作室 · 11-12
阳光诺和：关于董事暨审计与风险委员会委员辞职的公告
阳光诺和：张颖先生因个人原因申请辞去公司第二届董事会非独立董事职务，同时辞去公司第二届审计与风险委员会委员职务
每日经济新闻 · 11-12
阳光诺和：张颖先生因个人原因申请辞去公司第二届董事会非独立董事职务，同时辞去公司第二届审计与风险委员会委员职务
阳光诺和董事张颖辞职
财中社 · 11-12
阳光诺和董事张颖辞职
阳光诺和11月12日获主力加仓3350万元 环比增加1480.19%
市场透视 · 11-12
阳光诺和11月12日获主力加仓3350万元 环比增加1480.19%
阳光诺和创1个月新高 国家医保局推动检查检验项目价格下调
智选洞察 · 11-12
阳光诺和创1个月新高 国家医保局推动检查检验项目价格下调
阳光诺和：11月1日接受机构调研，国新证券、华能贵诚信托等多家机构参与
证券之星 · 11-05
阳光诺和：11月1日接受机构调研，国新证券、华能贵诚信托等多家机构参与
太平洋：给予阳光诺和买入评级
证券之星 · 10-31
太平洋：给予阳光诺和买入评级
阳光诺和：10月29日接受机构调研，广发证券、国盛证券等多家机构参与
证券之星 · 10-31
阳光诺和：10月29日接受机构调研，广发证券、国盛证券等多家机构参与
开源证券：给予阳光诺和买入评级
证券之星 · 10-30
开源证券：给予阳光诺和买入评级
阳光诺和和艺妙神州合作开发的CAR-T疗法获准进入系统性红斑狼疮临床试验阶段
美港电讯 · 10-30
阳光诺和和艺妙神州合作开发的CAR-T疗法获准进入系统性红斑狼疮临床试验阶段
阳光诺和大幅上涨 获主力净流入678万元
智选洞察 · 10-30
阳光诺和大幅上涨 获主力净流入678万元
阳光诺和（688621）2024年三季报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 10-30
阳光诺和（688621）2024年三季报简析：营收净利润同比双双增长，应收账款上升
阳光诺和：获得《药物临床试验批准通知书》
每日经济新闻 · 10-29
阳光诺和：获得《药物临床试验批准通知书》
暂无数据
公司概况
公司名称：
北京阳光诺和药物研究股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-06-21
主营业务：
北京阳光诺和药物研究股份有限公司主营业务是为医药企业提供专业化研发外包服务，致力于协助中国医药制造企业加速实现进口替代和自主创新。公司的主要包括药物发现、药理药效、药学研究、临床研究和生物分析。报告期内公司参与研发和自主立项研发的项目中，共8项新药项目已通过NMPA批准进入临床试验，70项药品申报上市注册受理，8项一致性评价注册受理；取得39项药品生产注册批件；7项通过一致性评价，6项原料药通过审评获批。
发行价格：
26.89
{"stockData":{"symbol":"688621","market":"SH","secType":"STK","nameCN":"阳光诺和","latestPrice":40.7,"timestamp":1732258801000,"preClose":42.74,"halted":0,"volume":2115561,"delay":0,"floatShares":112000000,"shares":112000000,"eps":1.9766,"marketStatus":"已收盘","marketStatusCode":5,"change":-2.04,"latestTime":"11-22 15:00:01","open":42.68,"high":42.78,"low":40.7,"amount":88585400,"amplitude":0.0487,"askPrice":40.7,"askSize":2,"bidPrice":40.68,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.9766,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":42.74,"symbolType":"stock_kcb","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":47.01,"lowLimit":38.47,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":112000000,"pbRate":4.03,"roa":"--","roe":"19.74%","epsLYR":1.65,"committee":-0.256997,"marketValue":4558000000,"floatMarketCap":4558000000,"peRate":20.590913,"changeRate":-0.0477,"turnoverRate":0.0189,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-11-25。","afterMarket":{"amount":0,"volume":0,"close":40.7,"buyVolume":0,"sellVolume":0,"time":1732260839464,"indexStatus":"已收盘 11-22 15:30:00","preClose":42.74}},"requestUrl":"/m/hq/s/688621/tweets","defaultTab":"tweets","newsList":[{"id":"2484183459","title":"阳光诺和：公司现在的新签订单中临床业务的占比已经接近50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484183459","media":"每日经济新闻","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484183459?lang=zh_cn&edition=full","pubTime":"2024-11-20 07:53","pubTimestamp":1732060402,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：目前公司创新药订单的占比是多少？阳光诺和（688621.SH）11月19日在投资者互动平台表示，公司临床业务经过多年临床项目经验的积累，在创新药大临床上形成了自己的优势适应症领域，目前在上海、北京、成都、南京等地均有布局，公司现在的新签订单中临床业务的占比已经接近50%。此外，在药学业务范畴内，我们还涉及部分改良型新药的研究工作。本公司创新药订单呈现出稳健增长的态势，自研立项并储备的1类创新药项目共计12项。同时，公司进一步强化了创新药临床业务的商务拓展力度，确保充足的在手订单，为公司的收入快速增长奠定了坚实基础。(记者 张喜威)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120075423a246e9ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120075423a246e9ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688621"],"gpt_icon":0},{"id":"2484834561","title":"阳光诺和：本公司暂未涉足CDMO委托生产服务领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2484834561","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484834561?lang=zh_cn&edition=full","pubTime":"2024-11-20 07:53","pubTimestamp":1732060398,"startTime":"0","endTime":"0","summary":"因阳光诺和也涉及持有品种再转让，以及下游客户受让药品之后的再委托生产。对此《征求意见稿》出台背景、具体第十七条、第十条涉及的影响有哪些？预计《征求意见稿》通过率怎么样？目前，本公司暂未涉足CDMO委托生产服务领域，故该制度对本公司的运营不构成重大影响。此外，该类征求意见稿在正式颁布之前，将历经一个公开征求公众意见的阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120075421abd06177&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120075421abd06177&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688621","BK0216"],"gpt_icon":0},{"id":"2484914783","title":"阳光诺和：11月15日接受机构调研，中金证券、国投瑞银等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2484914783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484914783?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:05","pubTimestamp":1732014301,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月19日阳光诺和发布公告称公司于2024年11月15日接受机构调研，中金证券、国投瑞银、华杰高景、海绵投资参与。公司2024年前三季度业绩稳定增长，实现营业收入9.17亿元，同比增长32.47%。实现归属于上市公司股东的净利润为5911.73万元，同比增长11.37%。公司前三季度研发费用1.20亿元，同比增长43.76%，第三季度研发费用5041.19万元，较上年同期增长69.38%，第三季度研发投入总额占营业收入的比例为14.25%，增加1.36个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900031285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688621","BK0216"],"gpt_icon":0},{"id":"2484911420","title":"阳光诺和：本公司自主研发并储备的产品，多于临床批件获取前后实现转让，并同时锁定后续服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2484911420","media":"证星董秘互动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484911420?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:00","pubTimestamp":1732014041,"startTime":"0","endTime":"0","summary":"本公司创新药订单呈现出稳健增长的态势，自研立项并储备的1类创新药项目共计12项。因阳光诺和也涉及持有品种再转让，以及下游客户受让药品之后的再委托生产。本公司自主研发并储备的产品，多于临床批件获取前后实现转让，并同时锁定后续服务。此外，该类征求意见稿在正式颁布之前，将历经一个公开征求公众意见的阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119190129a24584fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119190129a24584fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688621"],"gpt_icon":0},{"id":"2484179506","title":"阳光诺和2024Q3财报点评：Q3营收高增 自研品种不断推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2484179506","media":"长江证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484179506?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:00","pubTimestamp":1731772800,"startTime":"0","endTime":"0","summary":"事件描述公司发布了2024 年三季度报告，2024 年前三季度实现营业收入9.17 亿元，同比增长32.47%；实现归母净利润2.08 亿元，同比增长21.40%；实现扣非归母净利润2.02 亿元，同比增长20.19%。事件评论Q3 营收高增长，现金流改善显著。营收的高增长得益于公司进一步加强市场商务拓展，业务订单充足。2024 年第三季度公司研发费用为5041 万元，研发费用率达14.25%，公司坚持研发投入，研发费用率长期维持在较高水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111714061995be3eef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111714061995be3eef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688621"],"gpt_icon":0},{"id":"2483348066","title":"11月15日阳光诺和跌5.14%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483348066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483348066?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:12","pubTimestamp":1731658325,"startTime":"0","endTime":"0","summary":"证券之星消息，11月15日阳光诺和跌5.14%，收盘报42.6元，换手率2.18%，成交量2.44万手，成交额1.07亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500025154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"gpt_icon":0},{"id":"2483316103","title":"阳光诺和大幅下跌 获融资净买入1127万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483316103","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483316103?lang=zh_cn&edition=full","pubTime":"2024-11-15 14:31","pubTimestamp":1731652265,"startTime":"0","endTime":"0","summary":"11月15日，阳光诺和股价大幅下跌，截至14点31分，阳光诺和下跌5.19%，报42.58元/股，成交9429万元，换手率1.92%。资金动向截止发稿，阳光诺和获得主力净流出2099万元，其中超大单流出1608万元，大单流出490万元。融资融券方面，阳光诺和11月13日获得融资净买入1127万元，当日该股融资余额为3.60亿元，当较前一日增加3.24%，实现2连增；该股融券余额为22万元，融券余量为0.52万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115143119a239e7b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115143119a239e7b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688621","BK0216"],"gpt_icon":0},{"id":"2482778065","title":"阳光诺和：关于董事暨审计与风险委员会委员辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2482778065","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482778065?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:20","pubTimestamp":1731403200,"startTime":"0","endTime":"0","summary":"北京阳光诺和药物研究股份有限公司董事会于近日收到张颖先生递交的书面辞职报告，张颖先生因个人原因申请辞去公司第二届董事会非独立董事职务，同时辞去公司第二届审计与风险委员会委员职务。公司将按照法定程序尽快完成相关人员的补选工作，张颖先生在辞职后将继续履行董事、审计与风险委员会委员职责，直至公司选举出新任董事、审计与风险委员会委员为止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-12/doc-incvuxsf9544045.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-12/doc-incvuxsf9544045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","688621"],"gpt_icon":0},{"id":"2482207467","title":"阳光诺和：张颖先生因个人原因申请辞去公司第二届董事会非独立董事职务，同时辞去公司第二届审计与风险委员会委员职务","url":"https://stock-news.laohu8.com/highlight/detail?id=2482207467","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482207467?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:06","pubTimestamp":1731402402,"startTime":"0","endTime":"0","summary":"每经AI快讯，阳光诺和 11月12日晚间发布公告称，公司董事会于近日收到公司非独立董事、审计与风险委员会委员张颖先生递交的书面辞职报告，张颖先生因个人原因申请辞去公司第二届董事会非独立董事职务，同时辞去公司第二届审计与风险委员会委员职务，张颖先生离任后将不在公司以及子公司担任其他职务。2024年1至6月份，阳光诺和的营业收入构成为：CRO业务占比99.98%。截至发稿，阳光诺和市值为53亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112170841abb9794f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112170841abb9794f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688621"],"gpt_icon":0},{"id":"2482773552","title":"阳光诺和董事张颖辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2482773552","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482773552?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:05","pubTimestamp":1731402340,"startTime":"0","endTime":"0","summary":"公司董事会近日收到张颖递交的书面辞职报告，因个人原因申请辞去公司第二届董事会非独立董事职务，同时辞去审计与风险委员会委员职务。张颖离任后不再担任公司及子公司的其他职务。截至公告日，张颖未持有公司股票，且不存在未履行的承诺事项。2024年前三季度，阳光诺和实现收入9.17亿元，归母净利润2.08亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172934a2300589&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172934a2300589&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688621"],"gpt_icon":0},{"id":"2482726096","title":"阳光诺和11月12日获主力加仓3350万元 环比增加1480.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482726096","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482726096?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:20","pubTimestamp":1731396039,"startTime":"0","endTime":"0","summary":"11月12日, 阳光诺和股价涨1.00%，报收47.42元，成交金额2.12亿元，换手率3.93%，振幅5.67%，量比1.39。阳光诺和今日主力资金净流入3350万元，上一交易日主力净流入212万元，今日环比增加1480.19%。该股近5个交易日上涨1.89%，主力资金累计净流入1725万元；近20日主力资金累计净流出3270万元，其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112153828abb908b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112153828abb908b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688621"],"gpt_icon":0},{"id":"2482715860","title":"阳光诺和创1个月新高 国家医保局推动检查检验项目价格下调","url":"https://stock-news.laohu8.com/highlight/detail?id=2482715860","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482715860?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:27","pubTimestamp":1731378448,"startTime":"0","endTime":"0","summary":"消息解读国家医保局统一部署各省开展医疗服务价格规范治理，推动一批量大价高的检查检验项目合理下调价格，进一步减轻患者看病就医负担，推进各省间检查检验价格相对均衡。此次国家医保局选取4个检验项目开展第一批价格规范治理，包括血栓弹力图试验、糖化血红蛋白测定、B型钠尿肽测定和N端B型钠尿肽前体测定。11月8日起，河南全省公立医疗机构统一降低血栓弹力图试验、床旁糖化血红蛋白测定等5个检验项目价格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112102821a22e35da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112102821a22e35da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688621"],"gpt_icon":0},{"id":"2481790315","title":"阳光诺和：11月1日接受机构调研，国新证券、华能贵诚信托等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2481790315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481790315?lang=zh_cn&edition=full","pubTime":"2024-11-05 19:11","pubTimestamp":1730805117,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月5日阳光诺和发布公告称公司于2024年11月1日接受机构调研，国新证券、华能贵诚信托、中华联合保险、合众资产、华夏久盈参与。该股最近90天内共有7家机构给出评级，买入评级6家，增持评级1家。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500031946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","161027","688621"],"gpt_icon":0},{"id":"2479248703","title":"太平洋：给予阳光诺和买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479248703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479248703?lang=zh_cn&edition=full","pubTime":"2024-10-31 18:21","pubTimestamp":1730370076,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司近期对阳光诺和进行研究并发布了研究报告《Q3收入超预期，研发投入持续加大》，本报告对阳光诺和给出买入评级，当前股价为44.4元。 盈利预测与投资建议：我们预计2024年-2026年公司营收为12.42/16.37/21.43亿元，同比增长33.24%/31.83%/30.89%；归母净利为2.72/3.61/4.75亿元，同比增长47.33%/32.66%/31.68%，对应当前PE为18/14/10倍，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100037944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","601099"],"gpt_icon":0},{"id":"2479277066","title":"阳光诺和：10月29日接受机构调研，广发证券、国盛证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479277066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479277066?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:45","pubTimestamp":1730367927,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年10月31日阳光诺和发布公告称公司于2024年10月29日接受机构调研，广发证券、国盛证券、长江证券、太平洋证券、国海证券、海通证券、光大证券、华西证券、中泰证券、华安证券、华福证券、开源证券、中银证券、民生证券、国金证券、信达证券、东方证券、天风证券、方正证券、华创证券、宁银理财、德邦证券、浙商证券、兴业证券、财通证券、招商证券、中金证券、东北证券参与。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100037378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01776","BK1147","BK0276","161027","000776","BK1564","BK0028","688621","BK0216","SG9999001093.SGD","BK0183","BK0188","BK0012"],"gpt_icon":0},{"id":"2479733635","title":"开源证券：给予阳光诺和买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479733635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479733635?lang=zh_cn&edition=full","pubTime":"2024-10-30 23:43","pubTimestamp":1730303021,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,汪晋近期对阳光诺和进行研究并发布了研究报告《公司信息更新报告：单Q3营收同比快速增长，业绩表现持续亮眼》，本报告对阳光诺和给出买入评级，当前股价为44.55元。2024H1，公司取得生产批件的权益分成项目共5项，实现营业收入共333.91万元。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000045248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","161027"],"gpt_icon":0},{"id":"2479184562","title":"阳光诺和和艺妙神州合作开发的CAR-T疗法获准进入系统性红斑狼疮临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2479184562","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479184562?lang=zh_cn&edition=full","pubTime":"2024-10-30 10:39","pubTimestamp":1730255969,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1141","03347","159992","688621","BK1574","BK1576","06978","BK1583","159837","CAR","BK1515","BK4077","SLE","BK4022","09939","BK4230","159938","BK0216","BK1161"],"gpt_icon":0},{"id":"2479792218","title":"阳光诺和大幅上涨 获主力净流入678万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479792218","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479792218?lang=zh_cn&edition=full","pubTime":"2024-10-30 10:32","pubTimestamp":1730255553,"startTime":"0","endTime":"0","summary":"10月30日，阳光诺和股价大幅上涨，截至10点32分，阳光诺和上涨5.15%，报46.53元/股，成交4980万元，换手率0.99%，振幅6.60%。资金动向截止发稿，阳光诺和获得主力净流入678万元，其中超大单流入498万元，大单流入179万元。融资融券方面，阳光诺和10月28日获得融资净买入78万元，当日该股融资余额为2.99亿元，当较前一日增加0.26%；该股融券余额为27万元，融券余量为0.59万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030103253ab809f68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030103253ab809f68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688621","BK0216"],"gpt_icon":0},{"id":"2479726949","title":"阳光诺和（688621）2024年三季报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479726949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479726949?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:18","pubTimestamp":1730240329,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期阳光诺和发布2024年三季报。截至本报告期末，公司营业总收入9.17亿元，同比上升32.47%，归母净利润2.08亿元，同比上升21.4%。按单季度数据看，第三季度营业总收入3.54亿元，同比上升53.2%，第三季度归母净利润5911.73万元，同比上升11.37%。本报告期阳光诺和应收账款上升，应收账款同比增幅达49.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000005964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621"],"gpt_icon":0},{"id":"2479426687","title":"阳光诺和：获得《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2479426687","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479426687?lang=zh_cn&edition=full","pubTime":"2024-10-29 15:44","pubTimestamp":1730187889,"startTime":"0","endTime":"0","summary":"每经AI快讯，阳光诺和 10月29日晚间发布公告称，近日，北京阳光诺和药物研究股份有限公司与北京艺妙神州医药科技有限公司及其全资子公司厦门再妙生物科技有限公司合作研发项目“ZM001注射液”收到国家药品监督管理局核准签发的《药物临床试验批准通知书》的临床试验申请获得批准。ZM001拟用于治疗系统性红斑狼疮。截至发稿，阳光诺和市值为50亿元。道达号“个股趋势”提醒：1. 近30日内无机构对阳光诺和进行调研。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029154537a1f4849c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029154537a1f4849c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688621","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-06-21","address":"北京市昌平区科技园区双营西路79号院7号楼一层","stockEarnings":[{"period":"1week","weight":-0.0446},{"period":"1month","weight":-0.0695},{"period":"3month","weight":0.3095},{"period":"6month","weight":-0.1927},{"period":"1year","weight":-0.3887},{"period":"ytd","weight":-0.4142}],"companyName":"北京阳光诺和药物研究股份有限公司","boardCode":"AI0073","perCapita":"14943股","boardName":"研究和试验发展","registeredCapital":"11200万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 北京阳光诺和药物研究股份有限公司主营业务是为医药企业提供专业化研发外包服务，致力于协助中国医药制造企业加速实现进口替代和自主创新。公司的主要包括药物发现、药理药效、药学研究、临床研究和生物分析。报告期内公司参与研发和自主立项研发的项目中，共8项新药项目已通过NMPA批准进入临床试验，70项药品申报上市注册受理，8项一致性评价注册受理；取得39项药品生产注册批件；7项通过一致性评价，6项原料药通过审评获批。","serverTime":1732359803080,"listedPrice":26.89,"stockholders":"7495人(较上一季度增加47.34%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阳光诺和,688621,阳光诺和股票,阳光诺和股票老虎,阳光诺和股票老虎国际,阳光诺和行情,阳光诺和股票行情,阳光诺和股价,阳光诺和股市,阳光诺和股票价格,阳光诺和股票交易,阳光诺和股票购买,阳光诺和股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}